Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ: JUNS) has announced a strategic partnership with Zina Biopharmaceuticals to advance its Phase 2a clinical trial for Parkinson's disease. The trial will evaluate JOTROL™, Jupiter's patented resveratrol-based therapeutic platform, focusing on safety, tolerability, and pharmacokinetics/pharmacodynamics in Parkinson's patients.
JOTROL's micellar formulation addresses historical resveratrol limitations by enhancing bioavailability while reducing gastrointestinal side effects. Preclinical studies have shown promise in reducing neurodegeneration biomarkers. Under the agreement, Zina will provide comprehensive services including protocol design, regulatory strategy, and trial site selection.
The partnership aims to accelerate development for the Parkinson's market, which affects over 10 million people globally and is projected to exceed $14 billion by 2030. Jupiter is also exploring additional partnerships to expand JOTROL's applications in other neuroinflammatory and metabolic disorders.
Positive
- Advancing to Phase 2a clinical trials for Parkinson's disease
- Strategic partnership secured for comprehensive trial support
- Preclinical studies show positive results in neurodegeneration biomarkers
- Targeting large market opportunity ($14B by 2030)
- Enhanced drug bioavailability with reduced side effects
Negative
- Early-stage clinical development with no proven efficacy yet
- Operating in highly competitive market with established players
- No current revenue generation from product
News Market Reaction 1 Alert
On the day this news was published, JUNS declined 8.20%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC ("Zina") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease.
Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL™, Jupiter’s patented resveratrol-based therapeutic platform. The primary objective of the trial will be to evaluate the safety and tolerability of JOTROL in patients with Parkinson’s, with secondary and exploratory endpoints to assess pharmacokinetics/pharmacodynamics (PK/PD) of the drug.
JOTROL’s innovative micellar formulation overcomes the historical limitations of resveratrol by achieving significantly enhanced bioavailability while minimizing gastrointestinal side effects. Preclinical studies have demonstrated JOTROL’s potential in mitigating key biomarkers associated with neurodegeneration, supporting its potential application in Parkinson’s disease and other central nervous system (CNS) disorders.
“This partnership with Zina marks a significant milestone for Jupiter as we advance JOTROL into Phase 2 clinical development for Parkinson’s,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Zina’s extensive expertise in trial execution, as well as regulatory, clinical and scientific strategy, will be instrumental in accelerating our development timeline and positioning us for future pivotal studies.”
Under the agreement, Zina will assist with clinical trial protocol design, including pharmacokinetics and biomarkers, regulatory strategy, and trial site selection to facilitate a smooth trial execution and future clinical progression.
Parkinson’s disease affects over 10 million people worldwide, with no disease-modifying treatments currently available. The global Parkinson’s therapeutics market is projected to exceed
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity medicine.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022.
About Zina Biopharmaceuticals, LLC
Zina Biopharmaceuticals is a specialized consulting company providing end-to-end trial design and execution solutions as well as regulatory, scientific and medical advice for biotech and pharmaceutical companies.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
What are the main objectives of JUNS Phase 2a Parkinson's trial?
How does JOTROL's formulation improve upon traditional resveratrol treatments?
What is the market potential for JUNS's Parkinson's treatment?
What role will Zina Biopharmaceuticals play in JUNS's Phase 2a trial?
What other therapeutic areas is JUNS exploring for JOTROL?
